CBD company Chanelle McCoy Health has received approval to start a trial which may allow it to sell its CBD sleeping aid as an over-the-counter (OTC) drug in Australian pharmacies.

The British brand has received ethics approval to begin the third and last phase of an efficacy clinical trial before its synthetic CBD formulation can be marketed in Australia as a non-prescription treatment for sleeping difficulties No CBD product has so far received authorisation to be sold as an OTC medicine in pharmacies in Australia.

Read full article
I'm already a subscriber

Tiziana Cauli

Senior reporter
Tiziana is an Italian journalist from Sardinia. She has worked for both international and local media in Italy, South Africa, France, Spain, the UK, Lebanon and Belgium. She also worked as a communications manager for several international NGOs in the humanitarian sector.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization